Chromosome aberrations in lymphocytes from women irradiated for benign and malignant gynecological disease

Journal Article · Fri Jul 01 04:00:00 EDT 1994 · Radiation Research

DOI:https://doi.org/10.2307/3578730· OSTI ID:81208

Kleinerman, R A; Boice, Jr, J D; Inskip, P D; Tarone, R E ^[1]; Littlefield, L G; Sayer, A M ^[2]; Cookfair, D L ^[3]; Wactawski-Wende, J ^[4]; Block, A W; Ramesh, K H ^[5]

---

1. National Institutes of Health, Bethesda, MD (United States)
2. Oak Ridge Institute for Science and Education, Oak Ridge, TN (United States)
3. Univ. of Buffalo SUNY, Buffalo, NY (United States)
4. School of Medicine and Biomedical Sciences, SUNY/Buffalo, NY (United States)
5. Roswell Park Cancer Institute, Buffalo, NY (United States)

Excess leukemias have occurred after partial-body radiotherapy for cervical cancer and benign gynecological disease (BGD). However, the level of risk is nearly the same in both groups, about twofold, despite a tenfold difference in average dose to active bone marrow. High-dose cell killing has been postulated as one explanation for this apparent inconsistency. To examine whether chromosome aberration rates observed in lymphocytes many years after exposure might serve as population markers of cancer risk, blood samples were taken from 60 women treated for BGD (34 with radiation) and cytogenetic data compared with previous results from 96 women irradiated for cervical cancer. Remarkably, the rate of stable aberrations, which reflects nonlethal damage in surviving stem cells, was only slightly higher among the cancer patients. Thus the lower-dose regimens to treat benign disorders resulted in much higher aberration yields per unit dose than those for cervical cancer. Assuming that the fraction of cytogenetically aberrant stem cells that survive radiotherapy contributes to the leukemogenic process, these data are then consistent with the epidemiological observations of comparable overall leukemia risks seen in these two irradiated populations. Accordingly, for patient populations given partial-body radiotherapy, stable aberrations at a long time after exposure appear to serve as biomarkers of effective risk rather than as biomarkers of radiation dose received. 30 refs., 4 tabs.

• Sponsoring Organization: USDOE
• DOE Contract Number: AC05-76OR00033
• OSTI ID: 81208
• Journal Information: Radiation Research, Journal Name: Radiation Research Journal Issue: 1 Vol. 139; ISSN 0033-7587; ISSN RAREAE
• Country of Publication: United States
• Language: English

Related Subjects

56 BIOLOGY AND MEDICINE
APPLIED STUDIES
BIOLOGICAL INDICATORS
BONE MARROW
CELL KILLING
CHROMOSOMAL ABERRATIONS
DISEASE INCIDENCE
DOSE-RESPONSE RELATIONSHIPS
GYNECOLOGY
LEUKEMIA
LYMPHOCYTES
RADIOTHERAPY
REPRODUCTIVE DISORDERS
WOMEN